de Oliveira Cardoso Cristiano, Elgalad Abdelmotagaly, Li Ke, Perin Emerson C
Center for Preclinical Surgical and Interventional Research, Texas Heart Institute, Houston, TX, United States.
Center for Clinical Research, Texas Heart Institute, Houston, TX, United States.
Front Cardiovasc Med. 2022 Sep 21;9:962839. doi: 10.3389/fcvm.2022.962839. eCollection 2022.
Congestive heart failure (HF) is a devastating disease leading to prolonged hospitalization, high morbidity and mortality rates, and increased costs. Well-established treatments for decompensated or unstable patients include medications and mechanical cardiac support devices. For acute HF decompensation, new devices are being developed to help relieve symptoms and recover heart and renal function in these patients. A recent device-based classification scheme, collectively classified as DRIPS, has been proposed to better describe these new device-based therapies based on their mechanism: dilators (increase venous capacitance), removers (direct removal of sodium and water), inotropes (increase left ventricular contractility), interstitials (accelerate removal of lymph), pushers (increase renal arterial pressure), pullers (decrease renal venous pressure), and selective (selective intrarenal drug infusion). In this review, we describe the new class of medical devices with the most current results reported in preclinical models and clinical trials.
充血性心力衰竭（HF）是一种严重的疾病，会导致住院时间延长、高发病率和死亡率以及成本增加。对于失代偿或不稳定患者，已确立的治疗方法包括药物治疗和机械心脏支持装置。针对急性心力衰竭失代偿，正在研发新的装置以帮助缓解这些患者的症状并恢复心脏和肾功能。最近提出了一种基于装置的分类方案，统称为DRIPS，以根据其机制更好地描述这些基于新装置的疗法：扩张器（增加静脉容量）、清除器（直接清除钠和水）、正性肌力药（增加左心室收缩力）、间质剂（加速淋巴清除）、推动器（增加肾动脉压力）、拉动器（降低肾静脉压力）和选择性（选择性肾内药物输注）。在本综述中，我们描述了在临床前模型和临床试验中报告了最新结果的新型医疗装置。
